Reorganization of serum analysis tools for the diagnosis of bullous pemphigoid.

Reorganization of serum analysis tools for the diagnosis of bullous pemphigoid. Br J Dermatol. 2019 May;180(5):980-981 Authors: Yamagami J PMID: 31025727 [PubMed - in process]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research

Related Links:

This report describes a 70-year-old woman with LPP who presented with extensive erosions mimicking TEN. This case also highlights the need to consider important etiologies such as drug-induced and paraneoplastic LPP.
Source: The American Journal of Dermatopathology - Category: Pathology Tags: Extraordinary Case Report Source Type: research
Authors: Usami J, Takezawa Y PMID: 31611529 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Condition:   Bullous Pemphigoid Intervention:   Drug: Rituximab combined with Omalizumab Sponsor:   University of California, Davis Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Autoimmune blistering diseases (AIBDs) of the skin are characterized by autoantibodies against different intra-/extracellular structures within the epidermis and at the basement membrane zone (BMZ). Binding of the antibodies to their target antigen leads to inflammation at the respective binding site and degradation of these structures, resulting in the separation of the affected skin layers. Clinically, blistering, erythema and lesions of the skin and/or mucous membranes can be observed. Based on the localization of the autoantigen, AIBDs can be divided into pemphigus (intra-epidermal blistering diseases) and pemphigoid d...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
S Karthik, PE Joseph, T BabuJournal of Postgraduate Medicine 2019 65(4):244-246 Dipeptidyl peptidase-4 inhibitors (DPP-4i) are one of the mainstay drugs in the management of type 2 diabetes mellitus. It has been well-documented that these class of drugs cause allergic reactions. Bullous pemphigoid (BP) is a blistering skin condition commonly associated with many drugs. Here, we report a case of probable DPP-4i-induced BP in an elderly man, which resolved on discontinuation of the drug. Although this adverse drug reaction has been documented in Western world and Japanese ethnicity, this seems to be the first case report of...
Source: Journal of Postgraduate Medicine - Category: Internal Medicine Authors: Source Type: research
Pembrolizumab is a humanized antibody that targets the programmed death-1 receptor expressed in T cells with high selectivity. This therapeutic is of great importance in cancer immunotherapy yet managing the potential immune-related adverse events remains a concern. Here, we report a rare case of mucous membrane pemphigoid in the oral mucosa, upper respiratory tract, and conjunctiva of a patient with ovarian adenocarcinoma without cutaneous manifestation, which persisted even after pembrolizumab discontinuation. A brief review of pembrolizumab-related bullous pemphigoid cases is presented and possible mechanisms underlying...
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research
This study aimed to evaluate the association of autoimmune bullous diseases [bullous pemphigoid (BP) and pemphigus vulgaris (PV)] with radiotherapy (RT) among patients with breast cancer from a population-based Taiwanese database. The case –control study included 365 women with BP or PV and 1460 randomly selected propensity score-matched controls without BP or PV. We compared the prevalences of prior RT and breast cancer between the cases and controls. In addition, we performed multivariable logistic regression analysis to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) for developing BP or PV acco...
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
Condition:   Bullous Pemphigoid Intervention:   Drug: Ustekinumab Sponsor:   CHU de Reims Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Dermatology | Pemphigoid | Skin | UK Health